What is the best way to manage patients with intermediate-risk prostate cancer? One of the most controversial aspects of treatment is the role of short-term androgen deprivation therapy in combination with definitive radiotherapy. In two randomised trials of patients with mostly intermediate-risk prostate cancer, increased overall survival was reported when short-term androgen deprivation therapy was added to radiotherapy. However, radiation doses in these studies were far below the current standard of care. This limitation, in combination with the heterogeneous nature of the cancers classified as intermediate risk, has complicated the application of these trial results to modern clinical practice. In this Review, we discuss clinical evidence for and against use of short-term androgen deprivation therapy with dose-escalated radiotherapy for patients with intermediate-risk prostate cancer.
Written by:
Zumsteg ZS, Zelefsky MJ Are you the author?
Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Reference: Lancet Oncol. 2012 Jun;13(6):e259-69
doi: 10.1016/S1470-2045(12)70084-0
PubMed Abstract
PMID: 22652234